SCHEMBL19949874

SCHEMBL19949874

CNCc1cc(C)c(-c2nc3c(-c4cccnc4)n[nH]c3cc2C#N)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 6/20 0.44
MAP4K1 Q92918 5/20 0.44
KIT P10721 4/20 0.44
FLT3 P36888 4/20 0.44
MAP2K4 P45985 1/20 0.39
LRRK2 Q5S007 2/20 0.38
EPHX2 P34913 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
PIM1 P11309 4/20 0.37
KDM5A P29375 1/20 0.35
CLK2 P49760 2/20 0.35
CLK3 P49761 2/20 0.35
DYRK1A Q13627 2/20 0.35
IDO1 P14902 1/20 0.34
ADORA1 P30542 1/20 0.34
AXL P30530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19949830 0.83 MAP4K1 (0.63) NTRK1MAP4K1KITFLT3
SCHEMBL19949911 0.83 MAP4K1 (0.41) NTRK1MAP4K1KITFLT3LRRK2
SCHEMBL19949839 0.83 MAP4K1 (0.41) NTRK1MAP4K1KITFLT3LRRK2
SCHEMBL19949869 0.80 MAP4K1 (0.45) NTRK1MAP4K1KITFLT3
SCHEMBL19960797 0.79 MAP4K1 (0.46) NTRK1MAP4K1KITFLT3
SCHEMBL19949764 0.79 MAP4K1 (0.46) NTRK1MAP4K1KITFLT3
SCHEMBL19949834 0.79 MAP4K1 (0.41) NTRK1MAP4K1KITFLT3LRRK2
SCHEMBL19949930 0.79 MAP4K1 (0.44) NTRK1MAP4K1KITFLT3LRRK2
SCHEMBL19964796 0.76 MAP4K1 (0.42) NTRK1MAP4K1KITFLT3LRRK2
SCHEMBL20791761 0.76 MAP4K1 (0.49) NTRK1MAP4K1KITFLT3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 US claimed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 US claimed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 US claimed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US claimed
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 US disclosed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 US disclosed
US-11891388-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-02-06 US disclosed
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-07-21 US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 US disclosed
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-09-10 US disclosed
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-09-10 US disclosed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 US disclosed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 US disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049214-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885
US-11242343-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885
US-11891388-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 NTRK1 2377/4885MAP4K1 41/4885KIT 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.